Celltrion Calls For Harmonized Approach To ‘Biobetters’
As Latest Data Shows Benefits Of Subcutaneous Infliximab Biosimilar Remsima SC
Executive Summary
A standardized, globally-accepted approach to ‘biobetters’ – biosimilars that offer improvements over the original reference drug – is needed to reduce trial duplication and allow products to come to market more quickly, Celltrion tells Generics Bulletin, at the same time as the company published data showing the benefits of its Remsima SC unique subcutaneous formulation of infliximab.
You may also be interested in...
‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars
Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.
Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’
Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.
Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO
Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.